Volume 17, Number 3—March 2011
Dispatch
Laboratory-based Surveillance of Extensively Drug-Resistant Tuberculosis, China
Yunfeng Deng, Yan Wang, Junling Wang, Hui Jing, Chunbao Yu, Haiying Wang, Zhimin Liu, Edward A. Graviss, and Xin Ma
Table 1
First- and second-line drug resistance of 989 clinical Mycobacterium tuberculosis isolates, People’s Republic of China, November 2004–April 2007*
| Drugs* | No. isolates | Rate, % |
|---|---|---|
| Overall first-line drug resistance | 319 | 32.3 |
| INH | 187 (44) | 18.9 (4.4) |
| RFP | 159 (16) | 16.1 (1.6) |
| EMB | 46 (0) | 4.7 (0) |
| SM |
238 (78) |
24.1 (7.9) |
| MDR, overall | 107 | 10.8 |
| INH + RFP | 16 | 1.6 |
| INH + RFP + EMB | 2 | 0.2 |
| INH + RFP + SM | 58 | 5.9 |
| INH + RFP + EMB + SM |
31 |
3.1 |
| Overall second-line drug resistance | 189 | 19.1 |
| FQ | 162 (103) | 16.4 (10.4) |
| AMK | 32 (0) | 3.2 (0) |
| CPM | 56 (14) | 5.7 (1.4) |
| PAS |
37 (6) |
3.7 (0.6) |
| Second-line drug polyresistance | 66 | 6.6 |
| FQ + AMK | 8 | 0.8 |
| FQ + AMK + CPM | 9 | 0.9 |
| FQ + AMK + PAS | 4 | 0.4 |
| FQ + AMK + CPM + PAS | 6 | 0.6 |
| FQ + CPM | 15 | 1.5 |
| FQ + PAS | 10 | 1.0 |
| FQ + CPM + PAS | 7 | 0.7 |
| AMK + CPM | 3 | 0.3 |
| AMK + PAS | 1 | 0.1 |
| AMK + CPM + PAS | 1 | 0.1 |
| CPM + PAS | 2 | 0.2 |
*Numbers and rates of mono–first- and -second–line drug-resistant strains shown in parentheses. INH, isoniazid; RFP, rifampin;, EMB, ethambutol; SM, streptomycin; MDR, multidrug-resistant; FQ, fluoroquinolines (specifically ciprofloxacin and levofloxacin); AMK, amikacin; CPM, capreomycin; PAS, para-aminosalicylic acid.
